Provention Bio
Edit

Provention Bio

http://www.proventionbio.com/
Last activity: 06.01.2023
Active
Categories: BioTechBuildingDevelopmentDrugFoodTechITJobLearnLifeProduct
Provention Bio is a biopharmaceutical company focused on advancing the development of investigational therapies that may intercept and prevent debilitating and life-threatening immune-mediated diseases. At Provention Bio, we approach autoimmune disease differently than traditional pharma, with a clear focus on early interception. Before symptoms present, before irreversible damage is done to the bodies, minds, and lives of patients and families, and before it’s too late —this is where we operate. Our lead investigational product candidate is currently under review by the U.S. Food and Drug Administration (FDA) for the delay or prevention of clinical type 1 diabetes in at-risk individuals. Our pipeline includes additional clinical-stage product candidates for autoimmune diseases, including celiac disease and lupus. We have a vision to change the world by unleashing the full potential of lives otherwise burdened or cut short by autoimmune disease. It may seem daunting, but once we realize the potential of every moment we can protect—in every life we can change—the work we do at Provention Bio becomes more than just a job. It becomes a calling.

Provention Bio is an Equal Opportunity Employer.

We invite you to learn more at www.ProventionBio.com and connect by following us on LinkedIn and Twitter (@ProventionBio).
Followers
612
Website visits
3.9K /mo.
Mentions
34
Location: United States, New Jersey, Red Bank
Employees: 51-200
Total raised: $28.4M
Founded date: 2017

Investors 1

DateNameWebsite
-T1D Fundt1dfund.or...

Funding Rounds 1

DateSeriesAmountInvestors
26.06.2017-$28.4M-

Mentions in press and media 34

DateTitleDescription
06.01.2023Provention Bio Announces the Grant of Inducement AwardsRED BANK, N.J., January 6, 2023 /PRNewswire/ -- Provention Bio, Inc. PRVB (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that the Company granted sto...
05.02.2022Provention Bio Announces the Grant of Inducement AwardRED BANK, N.J., Feb. 4, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that the Company gran...
28.01.2022Provention Bio Resubmitting Biologics License Application for Delay of Clinical Type 1 Diabetes in At-Risk Individuals Following Type B Meeting with the FDARED BANK, N.J., Jan. 27, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced its intent to resubm...
21.01.2022Provention Bio Announces Initiation of the Phase 2a PREVAIL-2 Study of PRV-3279 (CD32B × CD79 Bispecific DART® Molecule) in Systemic Lupus Erythematosus (SLE)RED BANK, N.J., Jan. 20, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced the initiation of the Phase 2a PREVAIL-2 study ...
07.01.2022Provention Bio Announces the Grant of Inducement AwardsRED BANK, N.J., Jan. 7, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that the Company gran...
20.12.2021Provention Bio Announces Leadership Team ExpansionRED BANK, N.J., Dec. 20, 2021 /PRNewswire/ -- December 20, 2021— Provention Bio, Inc. (NASDAQ: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced t...
02.12.2021Provention Bio Announces the Grant of Inducement AwardsRED BANK, N.J., Dec. 2, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that the Company gran...
04.11.2021Provention Bio Reports Third Quarter 2021 Financial Results and Provides Business UpdateRED BANK, N.J., Nov. 4, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today reported financial results for the third quarter ended Sep...
04.11.2021Provention Bio Announces Appointment of Thierry Chauche as Chief Financial OfficerRED BANK, N.J., Nov. 4, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that Thierry Chauche will become Chief Financial...
26.10.2021Provention Bio Announces Positive Interim Results from First-In-Human Study of Coxsackievirus B Vaccine Candidate PRV-101RED BANK, N.J., Oct. 26, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced positive interim results from PROVENT (PROtocol...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In